Ofev (Nintedanib)

Nintedanib inhibits several receptor tyrosine kinases, including VEGFR, PDGFR and FGFR. By blocking these signals it reduces fibroblast proliferation, migration and transformation, and also limits new blood‑vessel formation, which together help control fibrotic tissue and tumor growth.

The exact dose of Ofev is set by the prescribing clinician based on the approved indication, patient weight, renal and hepatic function, and any concomitant medications. No fixed regimen is provided here; dosing decisions are individualized by the treating physician.

Nintedanib is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and women of child‑bearing potential must use effective contraception. Safety during breastfeeding has not been established, so avoidance is recommended.

To place an order, submit an enquiry on the Ofev product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The primary alternative for fibrotic lung disease is pirfenidone, another antifibrotic agent. While both slow disease progression, nintedanib targets multiple tyrosine kinases, offering broader anti‑angiogenic activity, whereas pirfenidone’s mechanism centers on reducing fibroblast activation. Choice depends on patient tolerance, comorbidities and physician judgment.

Ofev capsules should be stored below 25 °C in their original packaging, protected from moisture and direct sunlight. Do not store in a bathroom or other humid environment, and keep the container tightly closed when not in use.

Ofev is taken orally as a hard gelatin capsule. It should be swallowed whole with a glass of water, preferably with food to lessen gastrointestinal discomfort. The capsule should not be opened, chewed, or crushed.

The most serious adverse events include hepatotoxicity (significant liver enzyme elevations or liver injury), severe bleeding (including gastrointestinal hemorrhage), and cardiovascular events such as myocardial infarction or stroke. Patients should be monitored regularly for signs of these conditions.

Ofev is contraindicated in pregnant women, patients with severe hepatic impairment, and those with active, uncontrolled bleeding. Caution is also advised for individuals with recent major cardiovascular events or uncontrolled hypertension. Clinicians must evaluate each patient’s medical history before initiating therapy.